Olmeamlo Hct (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmeamlo Hct is indicated for hypertension, a condition characterized by elevated arterial pressure, and works within the cardiovascular system to lower blood pressure.

• Hypertension: helps achieve target blood pressure levels and reduces cardiovascular risk.
• Hypertension resistant to monotherapy: provides additional blood pressure reduction when a single agent is insufficient.
• Hypertension with fluid retention: combines a diuretic to address volume overload while lowering pressure.

• The combination product lowers blood pressure through three complementary mechanisms: olmesartan medoxomil blocks the angiotensin II type 1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, causing arterial dilation; and hydrochlorothiazide promotes renal excretion of sodium and water, decreasing plasma volume. Together these actions produce additive antihypertensive effects.

Adverse reactions may vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate headache.
• Peripheral edema: swelling of the ankles or feet.
• Dizziness or light‑headedness: especially after standing.
• Flushing: transient warmth and redness.
• Fatigue: general tiredness.
• Nausea: mild stomach upset.

Serious or Rare Side Effects

• Angio‑edema: rapid swelling of face, lips or throat.
• Severe hypotension: marked drop in blood pressure causing fainting.
• Electrolyte imbalance: significant changes in potassium or sodium levels.
• Acute kidney injury: sudden decline in renal function.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Severe skin reactions: such as Stevens‑Johnson syndrome.

Before initiating therapy, consider the following safety measures:

• Renal function: assess baseline kidney function and monitor periodically.
• Electrolytes: check serum potassium and sodium levels, especially with diuretic use.
• Cardiovascular status: evaluate for heart failure or recent myocardial infarction.
• Pregnancy and lactation: avoid use unless clearly needed; discuss risks with a healthcare professional.
• Drug hypersensitivity: review patient history for allergies to any component.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmeamlo Hct may interact with several drug classes; monitoring and dose adjustments are often required.

Major Interactions (Avoid)

• Aliskiren: concurrent use with ACE inhibitors or ARBs can increase risk of renal impairment.
• Potassium‑saving diuretics or supplements: may cause hyperkalaemia.
• Lithium: increased lithium levels and toxicity risk.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function.
• CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): can raise amlodipine concentrations.
• Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.